Sophie E Holmes, PhD
DownloadHi-Res Photo
Cards
Appointments
Psychiatry
Primary
Neurology
Secondary
Titles
Assistant Professor, Neurology
Contact Info
Appointments
Psychiatry
Primary
Neurology
Secondary
Titles
Assistant Professor, Neurology
Contact Info
Appointments
Psychiatry
Primary
Neurology
Secondary
Titles
Assistant Professor, Neurology
Contact Info
About
Titles
Assistant Professor of Psychiatry
Assistant Professor, NeurologyAppointments
Psychiatry
Assistant ProfessorPrimaryNeurology
Assistant ProfessorSecondary
Other Departments & Organizations
- Janeway Society
- Neurology
- NeuroPET Imaging Program
- Psychiatric Symptoms in Neurology Research Program
- Psychiatry
- Yale Depression Research Program
Education & Training
- PhD
- University of Manchester (2015)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Sophie E Holmes's published research.
Publications Timeline
A big-picture view of Sophie E Holmes's research output by year.
David Matuskey, MD
Richard Carson, PhD
Maggie Taylor Davis, PhD
Mika Naganawa, PhD
Nabeel Nabulsi, PhD
Irina Esterlis, PhD
11Publications
884Citations
Publications
2024
Deficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder
Asch R, Worhunsky P, Davis M, Holmes S, Cool R, Boster S, Carson R, Blumberg H, Esterlis I. Deficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder. Journal Of Affective Disorders 2024, 361: 415-424. PMID: 38876317, DOI: 10.1016/j.jad.2024.06.025.Peer-Reviewed Original ResearchConceptsMetabotropic glutamate receptor 5Bipolar disorderGlutamate receptor 5Positron emission tomographyFear processingEmotional processingAssociated with greater activationEmotion processing taskAssociated with impulsivityFunctional brain differencesAssociated with functional alterationsParietal brain regionsPathology of BDIncreased cortical activityAssociated with difficultiesDepressive disorderHealthy comparisonReceptor availabilityBrain differencesPre/postcentral gyriAttention difficultiesGreater activationBrain regionsPsychomotor functionTreatment developmentMeasuring Synaptic Density and Dopamine Transporter Availability in Parkinson's Disease: A PET Imaging Study with 11C-UCB-J and 18F-FE-PE2I (P7-3.007)
Saadabad F, Volpi T, Honhar P, Naganawa M, Cayir S, Tinaz S, Gallezot J, angarita G, Holmes S, Carson R, Finnema S, Matuskey D. Measuring Synaptic Density and Dopamine Transporter Availability in Parkinson's Disease: A PET Imaging Study with 11C-UCB-J and 18F-FE-PE2I (P7-3.007). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205367.Peer-Reviewed Original ResearchAuthor Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 55. PMID: 38472206, PMCID: PMC10933370, DOI: 10.1038/s41531-024-00674-6.Peer-Reviewed Original ResearchSynaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse loss
2019
Lower synaptic density is associated with depression severity and network alterations
Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Lower synaptic density is associated with depression severity and network alterations. Nature Communications 2019, 10: 1529. PMID: 30948709, PMCID: PMC6449365, DOI: 10.1038/s41467-019-09562-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMajor depressive disorderPost-traumatic stress disorderLower synaptic densitySynaptic densityPositron emission tomographyFunctional connectivityNetwork alterationsSynaptic vesicle glycoprotein 2ASymptoms of depressionSynaptic lossDepressive disorderHealthy controlsNerve terminalsDepressive symptomsDepression severityUnmedicated individualsSynaptic connectionsEmission tomographyStress disorderVivo evidenceSymptomsDepressionSeverityDisordersAlterations
2018
Cerebellar and Prefrontal Cortical Alterations in PTSD: Structural and Functional Evidence
Holmes SE, Scheinost D, DellaGioia N, Davis MT, Matuskey D, Pietrzak RH, Hampson M, Krystal JH, Esterlis I. Cerebellar and Prefrontal Cortical Alterations in PTSD: Structural and Functional Evidence. Chronic Stress 2018, 2: 2470547018786390. PMID: 30035247, PMCID: PMC6054445, DOI: 10.1177/2470547018786390.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPosttraumatic stress disorderIntrinsic connectivity distributionMedial prefrontal cortexTensor-based morphometryPTSD groupFunctional connectivityPrefrontal cortexPathophysiology of PTSDGray matter volumeWhole-brain connectivityKey brain regionsMiddle temporal gyrusDorsolateral prefrontal cortexDefault mode networkCentral executive networkFunctional connectivity analysisPFC alterationsCortical alterationsHealthy comparison participantsAltered volumeFunctional alterationsMatter volumeUnmedicated individualsCerebellar involvementBrain regions
2017
Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study
Holmes SE, Hinz R, Conen S, Gregory CJ, Matthews JC, Anton-Rodriguez JM, Gerhard A, Talbot PS. Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. Biological Psychiatry 2017, 83: 61-69. PMID: 28939116, DOI: 10.1016/j.biopsych.2017.08.005.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAnterior cingulate cortexMajor depressive episodeMajor depressive disorderPositron emission tomographyTSPO availabilityDepressive episodeControl subjectsDepressive disorderTranslocator proteinPK11195 positron emission tomographySevere major depressive episodeEmission tomographySuicidal thinkingSuicidal thoughtsPrefrontal cortexInvolvement of inflammationPeripheral inflammatory markersPositron emission tomography studyAnti-inflammatory therapyHealthy control subjectsLeast moderate severityMedication-free patientsEmission tomography studiesTSPO-specific radioligandBrains of individualsTrajectories of depressive and anxiety symptoms in older adults: a 6‐year prospective cohort study
Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey‐Smith S, Fowler C, Ellis K, Martins RN, Salvado O, Doré V, Villemagne VL, Rowe CC, Laws SM, Masters CL, Pietrzak RH, Maruff P, Imaging B. Trajectories of depressive and anxiety symptoms in older adults: a 6‐year prospective cohort study. International Journal Of Geriatric Psychiatry 2017, 33: 405-413. PMID: 28736899, PMCID: PMC5773367, DOI: 10.1002/gps.4761.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAgedAllelesAlzheimer DiseaseAnxiety DisordersApolipoprotein E4AttentionBrain-Derived Neurotrophic FactorCognitionDepressive DisorderDisease ProgressionExecutive FunctionFemaleHumansLogistic ModelsMaleMiddle AgedPositron-Emission TomographyProspective StudiesQuality of LifeRisk FactorsSex FactorsConceptsOlder adultsAnxiety symptomsPredominant trajectoriesRisk factorsLatent growth mixture modelingAlzheimer's diseaseApolipoprotein epsilon 4 alleleSex-specific risk factorsLower attentional functionBinary logistic regression analysisEpsilon 4 alleleElevated depressive symptomsGrowth mixture modelingLogistic regression analysisQuality of lifePositron emission tomographyNormal older adultsSubthreshold depressiveMale sexBaseline predictorsDepressive symptomsVal66Met alleleClinical depressionLower executive functionAnxiety trajectoriesAltered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence
Holmes SE, Girgenti MJ, Davis MT, Pietrzak RH, DellaGioia N, Nabulsi N, Matuskey D, Southwick S, Duman RS, Carson RE, Krystal JH, Esterlis I, Friedman M, Kowall N, Brady C, McKee A, Stein T, Huber B, Kaloupek D, Alvarez V, Benedek D, Ursano R, Williamson D, Cruz D, Young K, Duman R, Krystal J, Mash D, Hardegree M, Serlin G. Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 8390-8395. PMID: 28716937, PMCID: PMC5547601, DOI: 10.1073/pnas.1701749114.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPosttraumatic stress disorderMGluR5 availabilityPositron emission tomographyGlutamate systemMetabotropic glutamate receptor 5Treatment of PTSDHuman posttraumatic stress disorderGlutamate receptor 5Mechanism-based treatmentsExpression of FKBP5Promising treatment targetHuman postmortem tissueTargeted pharmacological treatmentStress psychopathologyPharmacological treatmentExpression of proteinsReceptor 5MGluR5Treatment targetsPostmortem tissueEmission tomographyStress disorderPostmortem samplesPromising targetDisorders
2016
In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study
Holmes SE, Hinz R, Drake RJ, Gregory CJ, Conen S, Matthews JC, Anton-Rodriguez JM, Gerhard A, Talbot PS. In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study. Molecular Psychiatry 2016, 21: 1672-1679. PMID: 27698434, DOI: 10.1038/mp.2016.180.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMedicated patientsTSPO availabilityMicroglial activationMicroglial activityNegative symptomsAntipsychotic-naive groupBrain microglial activityRegular intramuscular injectionsPositron emission tomography studySubset of patientsAnti-inflammatory statePrimary negative symptomsBrain of adultAntipsychotic-free patientsPathophysiology of schizophreniaPotential modulatory effectsEmission tomography studiesHealthy comparison subjectsTranslocator proteinNegative Syndrome ScaleEmission Tomography ImagingPositron emission tomography (PET) imagingParietal cortical regionsAntipsychotic medicationMedicated schizophrenia
Clinical Trials
Current Trials
Ketamine for the Treatment of Depression in Parkinson's Disease
HIC ID2000030394RolePrincipal InvestigatorPrimary Completion Date08/31/2024Recruiting ParticipantsGenderBothAge40 years - 70 yearsEligibility for Participation in Neuroimaging Studies
HIC ID2000027842RoleSub InvestigatorPrimary Completion Date12/31/2023Recruiting ParticipantsStudying the Adult Brain
HIC ID2000025671RoleSub InvestigatorPrimary Completion Date07/31/2025Recruiting ParticipantsDysregulation in mGluR5 as a marker of BPD and suicide related endophenotypes
HIC ID2000023168RoleSub InvestigatorPrimary Completion Date10/31/2023Recruiting ParticipantsGenderBothAge18 years - 65 yearsExamination of Glutamate and mGluR5 in Psychiatric Disorders
HIC ID1101007933RoleSub InvestigatorPrimary Completion Date08/31/2022Recruiting ParticipantsGenderBothAge18 years - 65 years
Links & Media
News
- December 21, 2023
Holmes Named Recipient of CINP's Rafaelsen Young Investigators Award
- November 17, 2023Source: National Geographic
Ketamine Effectively Treats Depression. Do the Benefits Outweigh the Risks?
- June 01, 2023
Center for Brain and Mind Health First Annual Symposium
- February 21, 2023Source: Trembling EMT Podcast
Sanacora, Holmes Discuss Ketamine's Impact on Depression on Podcast